PharmacoEconomics

On Individual Preferences and Aggregation in Economic Evaluation in Healthcare
pp. 323-335(13)
Authors: Liljas B.; Lindgren B.

Pharmacoeconomics of Hypertension Management: The Place of Combination Therapy
pp. 337-347(11)
Author: Ambrosioni E.

Symptom and Health-Related Quality-of-Life Measures for Use in Selected Gastrointestinal Disease Studies: A Review and Synthesis of the Literature
pp. 349-363(15)
Authors: Rentz A.M.; Battista C.; Trudeau E.; Jones R.; Robinson P.; Sloan S.; Mathur S.; Frank L.; Revicki D.A.

Augmenting Reference Pricing of Pharmaceuticals in New Zealand with Strategic Cross-Product Agreements
pp. 365-377(13)
Author: Woodfield A.

The Cost of Treatment of Alzheimer's Disease in The Netherlands: A Regression-Based Simulation Model
pp. 379-390(12)
Authors: McDonnell J.; Redekop W.K.; van der Roer N.; Goes E.; Ruitenberg A.; Busschbach J.J.V.; Breteler M.M.B.; Rutten F.F.H.

Cost-Benefit Analysis of a Haemophilus Influenzae Type B Meningitis Prevention Programme in The Philippines
pp. 391-400(10)
Authors: Limcangco M.R.M.T.; Armour C.L.; Salole E.G.; Taylor S.J.

Cost Effectiveness of Continuous Terbinafine Compared with Intermittent Itraconazole in the Treatment of Dermatophyte Toenail Onychomycosis: An Analysis Based on Results from the L.I.ON. Study
pp. 401-410(10)
Authors: Jansen R.; Redekop W.K.; Rutten F.F.H.

Cost-Effectiveness Analysis of n-3 Polyunsaturated Fatty Acids (PUFA) after Myocardial Infarction: Results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial
pp. 411-420(10)
Authors: Franzosi M.G.; Brunetti M.; Marchioli R.; Marfisi R.M.; Tognoni G.; Valagussa F.

Efavirenz: A Pharmacoeconomic Review of its Use in HIV Infection
pp. 421-436(16)
Authors: Plosker G.L.; Perry C.M.; Goa K.L.